Weiss Ratings Reiterates Sell (D-) Rating for Co-Diagnostics (NASDAQ:CODX)

by · The Cerbat Gem

Co-Diagnostics (NASDAQ:CODX – Get Free Report)‘s stock had its “sell (d-)” rating reiterated by investment analysts at Weiss Ratings in a research report issued on Thursday,Weiss Ratings reports.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $3.00 target price on shares of Co-Diagnostics in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Co-Diagnostics has a consensus rating of “Moderate Buy” and a consensus price target of $2.00.

View Our Latest Research Report on Co-Diagnostics

Co-Diagnostics Trading Down 1.8%

NASDAQ:CODX opened at $0.46 on Thursday. The company has a market capitalization of $22.14 million, a P/E ratio of -0.40 and a beta of 0.93. Co-Diagnostics has a 12 month low of $0.23 and a 12 month high of $1.55. The business’s 50-day moving average is $0.39 and its 200 day moving average is $0.33.

Co-Diagnostics (NASDAQ:CODX – Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. The company had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.30 million. Co-Diagnostics had a negative return on equity of 69.49% and a negative net margin of 3,588.33%. On average, research analysts forecast that Co-Diagnostics will post -1.22 earnings per share for the current year.

Institutional Investors Weigh In On Co-Diagnostics

An institutional investor recently raised its position in Co-Diagnostics stock. Jane Street Group LLC raised its stake in shares of Co-Diagnostics, Inc. (NASDAQ:CODX – Free Report) by 314.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 166,254 shares of the company’s stock after purchasing an additional 126,105 shares during the period. Jane Street Group LLC owned 0.50% of Co-Diagnostics worth $47,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 14.99% of the stock is owned by hedge funds and other institutional investors.

Co-Diagnostics Company Profile

(Get Free Report)

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.

See Also